12:00 AM
Sep 07, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avastin bevacizumab: Final Phase II data

Final data from the open-label, pivotal Phase II BRAIN trial in 167 patients with recurrent GBM showed that 6-month PFS was observed in 42.6% of patients receiving Avastin monotherapy and in 50.3% of patients receiving Avastin plus irinotecan. The objective response rates for Avastin monotherapy and Avastin...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >